CHICAGO (Reuters) - Eli Lilly and Co said on Friday it withdrew an application to market its anti-depressant Cymbalta for the management of chronic pain because U.S. health regulators raised questions ...

The Food and Drug Administration recently approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. The ...

The U.S. Food and Drug Administration has approved Cymbalta for chronic back pain and osteoarthritis pain, according to a FDA news release. Cymbalta, which was first used to treat major depressive ...

The FDA has approved duloxetine (Cymbalta) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic low-back pain. Several recent randomized trials have evaluated ...

Indianapolis - Cymbalta may have been launched as an anti-depressant, but it offers relief for low back pain. According to our news gathering partners at the Indianapolis Star, that announcement came ...